1: Lakis S, Heukamp LC, Griesinger F. Detection of Discrepant Driver Mutations in a Patient with Two Synchronous Primary Non-Small Cell Lung Cancers (NSCLCs) with Liquid Biopsy. J Thorac Oncol. 2017 Nov;12(11):e186-e188. doi: 10.1016/j.jtho.2017.07.018. PMID: 29074212.
2: Müller JN, Falk M, Talwar J, Neemann N, Mariotti E, Bertrand M, Zacherle T, Lakis S, Menon R, Gloeckner C, Tiemann M, Heukamp LC, Thomas RK, Griesinger F, Heuckmann JM. Concordance between Comprehensive Cancer Genome Profiling in Plasma and Tumor Specimens. J Thorac Oncol. 2017 Oct;12(10):1503-1511. doi: 10.1016/j.jtho.2017.07.014. Epub 2017 Jul 24. PMID: 28751246.
3: Jóri B, Schatz S, Kaller L, Kah B, Roeper J, Ramdani HO, Diehl L, Hoffknecht P, Grohé C, Griesinger F, Tiemann M, Heukamp LC, Falk M. Comparison of Resistance Spectra after First and Second Line Osimertinib Treatment Detected by Liquid Biopsy. Cancers (Basel). 2021 Jun 8;13(12):2861. doi: 10.3390/cancers13122861. PMID: 34201252; PMCID: PMC8227553.
4: Jóri B, Falk M, Hövel I, Weist P, Tiemann M, Heukamp LC, Griesinger F. Acquired G2032R Resistance Mutation in ROS1 to Lorlatinib Therapy Detected with Liquid Biopsy. Curr Oncol. 2022 Sep 16;29(9):6628-6634. doi: 10.3390/curroncol29090520. PMID: 36135089; PMCID: PMC9497554.
